Brokerages Set Nabriva Therapeutics AG (NBRV) PT at $16.57
Nabriva Therapeutics AG (NASDAQ:NBRV) has been given a consensus recommendation of “Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.86.
Several equities research analysts have recently issued reports on NBRV shares. Zacks Investment Research cut Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Cantor Fitzgerald set a $16.00 target price on Nabriva Therapeutics AG and gave the stock a “buy” rating in a report on Monday, June 5th. ValuEngine raised Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, May 15th.
Nabriva Therapeutics AG (NASDAQ NBRV) traded up 2.78% during mid-day trading on Friday, reaching $8.50. The company had a trading volume of 243,932 shares. The stock has a 50 day moving average price of $9.92 and a 200-day moving average price of $10.40. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $12.75. The stock’s market capitalization is $228.12 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. Equities analysts anticipate that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 19,803 shares of Nabriva Therapeutics AG stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $10.50, for a total value of $207,931.50. Following the completion of the transaction, the insider now owns 2,373,387 shares in the company, valued at $24,920,563.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 241,923 shares of company stock valued at $2,567,274. 2.75% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new position in Nabriva Therapeutics AG during the fourth quarter valued at approximately $103,000. Royal Bank of Canada raised its position in Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 8,650 shares in the last quarter. Almanack Investment Partners LLC. bought a new position in Nabriva Therapeutics AG during the first quarter valued at approximately $1,870,000. Nationwide Fund Advisors bought a new position in Nabriva Therapeutics AG during the first quarter valued at approximately $2,074,000. Finally, Wellington Management Group LLP raised its position in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares in the last quarter. Institutional investors own 68.56% of the company’s stock.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.